Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12564509 | 1.00 | OPRM1 (0.54) | OPRM1OPRD1HPGDALDH1A1PKM | |
| SCHEMBL12564528 | 1.00 | OPRM1 (0.54) | OPRM1OPRD1HPGDALDH1A1PKM | |
| SCHEMBL1988658 | 1.00 | OPRM1 (0.54) | OPRM1OPRD1HPGDALDH1A1PKM | |
| SCHEMBL12564511 | 0.99 | OPRM1 (0.55) | OPRM1OPRD1HPGDALDH1A1PKM | |
| SCHEMBL12564523 | 0.99 | OPRM1 (0.55) | OPRM1OPRD1HPGDALDH1A1PKM | |
| SCHEMBL1987827 | 0.99 | OPRM1 (0.55) | OPRM1OPRD1HPGDALDH1A1PKM | |
| SCHEMBL1987025 | 0.99 | OPRM1 (0.55) | OPRM1OPRD1HPGDALDH1A1PKM | |
| SCHEMBL12564524 | 0.84 | OPRM1 (0.53) | OPRM1OPRD1 | |
| SCHEMBL1990579 | 0.84 | OPRM1 (0.53) | OPRM1OPRD1 | |
| SCHEMBL12564547 | 0.83 | OPRM1 (0.67) | OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609659-B2 | Substituted 3,8-diazabicyclo[3.2.1]octane compounds | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2013-12-17 | — | — | US | disclosed |
| EP-2338889-B1 | Diazacyclic compounds having affinity for opioid receptors | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2012-08-29 | — | — | EP | disclosed |
| EP-2338889-A1 | Diazacyclic compounds having affinity for opioid receptors | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2011-06-29 | — | — | EP | disclosed |
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2011-06-23 | — | — | US | disclosed |
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRD1 1/4885HPGD 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.